je.st
news
Merck to Present New Data for KEYTRUDA (pembrolizumab) at the American Association for Cancer Research 2016 Annual Meeting
2016-04-06 14:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Data Evaluating KEYTRUDA as a Single Agent and in Novel Combinations Across a Wide Range of Cancers to Be Presented KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new research investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in multiple tumor types, both as a single agent and in combination with other therapies, will be presented at this years American Association for Cancer Research (AACR) Annual Meeting in New Orleans, April 16 20. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558Kim Hamilton, 908-740-1863orInvestor:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
research
present
american
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||
|
|||